FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis

@article{Omar2002FDAAE,
  title={FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis},
  author={Mohamed A Omar and James P. Wilson},
  journal={Annals of Pharmacotherapy},
  year={2002},
  volume={36},
  pages={288 - 295}
}
OBJECTIVE: To determine the number of cases of statin-associated rhabdomyolysis reported to the Food and Drug Administration for 6 statins and to profile the cases. METHODS: A retrospective analysis of all domestic and foreign reports of statin-associated rhabdomyolysis between November 1997 and March 2000 was conducted. Outcome measures included the total number of reports (initial plus follow-up), the number of unique cases, age, gender, percentages of report codes and role codes, and… 

Tables from this paper

Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration.
TLDR
This study suggested that concomitant use of these two kinds of agents may be associated with a lower risk for fatal outcome, whereas renal dysfunction appeared to be associatedwith a higher risk for Fatal outcome among the HMG-CoA reductase inhibitor-associated rhabdomyolysis cases.
Statin-induced rhabdomyolysis: a comprehensive review of case reports.
TLDR
Research is needed to identify the role of exercise and rehabilitation following statin-induced rhabdomyolysis since muscle damage may be severe and may have long-term effects on muscle function.
Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin
TLDR
Rhabdomyolysis featured in nearly all of the reports of statin-associated rhabdomYolysis and the majority of reports listed multiple risk factors, although dependence on risk factors appeared to be stronger with simVastatin than atorvastatin.
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
TLDR
Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin, pravastsatin, and simvastsatin; combined statin-fibrate use increased risk, especially in older patients with diabetes mellitus.
Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database
TLDR
Characteristics of muscle-related adverse events with statins in the Thai population showed some similarities and differences compared with Western countries, and an attempt to avoid dangerous and well-known drug interactions among statin users should be implemented nationwide.
Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
TLDR
This study confirms prior evidence for rhabdomyolysis associations with daptomycin, macrolides, trimethoprim-sulfamethoxazole, linezolid, fluoroquinolones, and cefdinir, and identifies previously unknown rhabDomyolytic associations with meropenem, cefditoren,cefaclor, and piperacillin-tazobactam.
Simvastatin–Fluconazole Causing Rhabdomyolysis
TLDR
Patients receiving statins who have cancer may receive azole antifungals and other drugs that inhibit CYP3A4 during treatment, predisposing them to toxicity, and patients should be monitored closely for drug interactions.
Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use
TLDR
While there is good evidence suggesting improved outcomes with use of high dose statins, the potential drug interactions and adverse effects need close attention and patients started on statin therapy should be counselled regarding the signs and symptoms of muscle injury.
FDA Adverse Event Reports on Use of Sibutramine: An Exploratory Analysis
TLDR
Establishing a relationship between sibutramine consumption resulting in various adverse events is difficult, because of the various limitations of the AERS database, caution must be taken when interpreting the cases reported to the database.
A Narrative Review of Statin-Induced Rhabdomyolysis: Molecular Mechanism, Risk Factors, and Management
TLDR
Rhabdomyolysis can be prevented by reducing the risk factors, such as using CYP3A4 inhibitors, using high-dose statins, and strenuous physical activities, and there is no guarantee that patients will be free of this side effect.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Rhabdomyolysis and HMG-CoA Reductase Inhibitors
TLDR
Rhabdomyolysis is a rare but clinically important adverse event of statin monotherapy or combination therapy and thorough understanding of this condition may help prevent or minimize adverse health outcomes in patients receiving statin therapy.
Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
TLDR
The use of lovastatin in combination with gemfibrozil is to be discouraged because of the potential for severe myopathy and life-threatening rhabdomyolysis.
Statin—Fibrate Combination Therapy
TLDR
Combination therapy with a statin and fibrate offers significant therapeutic advantage for the treatment of severe or refractory mixed hyperlipidemia, but such a combination does increase the risk of myopathy, which rarely outweighs the established morbidity and mortality benefits of achieving lipid goals.
Efficacy and tolerability of simvastatin (MK-733).
A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia
TLDR
Not all lipid-lowering drugs have been studied adequately on a long term basis, so that medications given for an indefinite period must be reevaluated frequently.
A review of clinical trials comparing HMG-CoA reductase inhibitors.
TLDR
Although the currently available HMG-CoA reductase inhibitors differ in their relative hypolipidemic effects, as a class they constitute the most effective agents available to maximally reduce elevated concentrations of LDL-cholesterol.
A review of clinical trials comparing HMG-CoA reductase inhibitors.
TLDR
Although the currently available HMG-CoA reductase inhibitors differ in their relative hypolipidemic effects, as a class they constitute the most effective agents available to maximally reduce elevated concentrations of LDL-cholesterol.
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
  • W. Garnett
  • Biology, Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1995
TLDR
Although the HMG-CoA reductase inhibitors rarely have severe adverse effects, they may interact, in some cases dangerously, with other drugs, with food, and with disease states.
Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia
TLDR
The literature supports the comparable safety and tolerability of all 4 currently available H MG-CoA reductase inhibitors, and the choice of an HMG- coA reduCTase inhibitor should depend on the extent of cholesterol lowering needed to meet the recommended treatment goal established by the National Cholesterol Education Program.
Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
TLDR
Simvastatin significantly reduces TC, LDL, and apolipoprotein (apo) B (30%, 35%, and 27%, respectively), and these effects are larger than those of fenofibrate (19%, 22%, and 14%, respectively).
...
1
2
3
4
...